Vas Narasimhan, AP Images

Vas Narasimhan re­veals a dis­ap­point­ing out­look for No­var­tis' gener­ics unit, while lay­ing out the phar­ma's M&A strat­e­gy

As No­var­tis CEO Vas Narasimhan fig­ures out ex­act­ly what he wants to do with San­doz, the com­pa­ny re­vealed in its Q4 re­port that US sales for the gener­ics unit are ex­pect­ed to con­tin­ue on a down­hill slide in the new year — po­ten­tial­ly putting a damper on the prospects of a buy­out.

Narasimhan says he’ll wrap up his strate­gic re­view of San­doz and make a de­ci­sion by the end of the year at the lat­est. Mean­while, he laid out the com­pa­ny’s M&A strat­e­gy go­ing in­to 2022, as pub­lic stocks tum­ble and all signs point to a Big Phar­ma M&A hunt this year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.